Back
 WJA  Vol.5 No.2 , June 2015
Incidence of Nephropathy in HIV Infected Patients Receiving Highly Active Antiretroviral Therapy at Newlands Clinic: A Retrospective Study
Abstract: Introduction: HIV infected patients on antiretroviral therapy (ART) are at risk of developing nephropathy and therefore require monitoring of renal function. Some medications used in the management of HIV, opportunistic infections (OIs) and other comorbidities are nephrotoxic and may further compromise renal function, underlining the importance of regular monitoring of renal function. This study was designed to determine the incidence of nephropathy in HIV infected patients on antiretroviral therapy (ART) at Newlands Clinic and to determine the associated risk factors. Methodology: A retrospective cohort study was conducted involving 1986 HIV-1 infected participants who were commenced on ART between January 2007 and December 2013 at Newlands Clinic. The majority of participants were female (1340 (67.5%)). All participants were aged 18 or older at ART commencement. Participants with pre-existing nephropathy at baseline were excluded. Nephropathy was defined as two consecutive calculated creatinine clearances (CrCl) less than 60 ml/min by the Cockcroft-Gault equation, or two consecutive urine dipsticks positive for protein (≥30 g/L albumin). Data collected during routine patient visits were exported from the clinic’s database and analysed for incidence of nephropathy and risk factors. Results: During the follow-up period, 93 of the 1986 participants (4.7%) developed nephropathy. The estimated incidence rate (IR) of nephropathy was 1.45/100 person years (CI: 1.17 - 1.78). In the multivariate analysis, statistically significant risk factors were baseline age > 45 (HR 2.30, CI: 1.50 - 3.55), diabetes mellitus (HR 4.12, CI: 1.75 - 9.69), pulmonary tuberculosis (HR 2.00, CI: 1.28 - 3.12), and HIV wasting syndrome (HR 2.72, CI: 1.30 - 5.68). Conclusion: The incidence of nephropathy was low in this cohort. The traditional risk factors for renal disease; older age and diabetes mellitus were significant, as well as HIV wasting syndrome and pulmonary tuberculosis. HIV care should be complimented with proper diabetic care and patients that develop pulmonary tuberculosis, HIV wasting syndrome or are initiated on ART above 45 years require regular monitoring for early detection of nephropathy.
Cite this paper: Shamu, T. , Wellington, M. , Pascoe, M. , Gwanzura, L. and Ndhlovu, C. (2015) Incidence of Nephropathy in HIV Infected Patients Receiving Highly Active Antiretroviral Therapy at Newlands Clinic: A Retrospective Study. World Journal of AIDS, 5, 113-123. doi: 10.4236/wja.2015.52014.
References

[1]   Campbell, G.L.J., Ibrahim, F., Fisher, M., Holt, S.G., Hendry, B.M. and Post, F.A. (2009) Spectrum of Chronic Kidney Disease in HIV-Infected Patients. HIV Medicine, 10, 329-336.
http://dx.doi.org/10.1111/j.1468-1293.2008.00691.x

[2]   Gupta, S.K., Eustace, J.A., Winston, J.A., Boydstun, I.I., Ahuja, T.S., Rodriguez, R.A., Tashima, K.T., Roland, M., Franceschini, N., Palella, F.J., Lennox, J.L., Klotman, P.E., Nachman, S.A., Hall, S.D. and Szczech, L.A. (2005) Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 40, 1559-1585. http://dx.doi.org/10.1086/430257

[3]   Bruggeman, L.A., Ross, M.D., Tanji, N., Cara, A., Dikman, S., Gordon, R.E., Burns, G.C., D’Agati, V.D., Winston, J.A., Klotman, M.E. and Klotman, P.E. (2000) Renal Epithelium Is a Previously Unrecognized Site of HIV-1 Infection. Journal of the American Society of Nephrology, 11, 2079-2087.

[4]   Marras, D., Bruggeman, L.A., Gao, F., Tanji, N., Mansukhani, M.M., Cara, A., Ross, M.D., Gusella, G.L., Benson, G., D’Agati, V.D., Hahn, B.H., Klotman, M.E. and Klotman, P.E. (2002) Replication and Compartmentalization of HIV-1 in Kidney Epithelium of Patients with HIV-Associated Nephropathy. Nature Medicine, 8, 522-526. http://dx.doi.org/10.1038/nm0502-522

[5]   Barisoni, L., Bruggeman, L.A., Mundel, P., D’Agati, V.D. and Klotman, P.E. (2000) HIV-1 Induces Renal Epithelial Dedifferentiation in a Transgenic Model of HIV-Associated Nephropathy. Kidney International, 58, 173-181. http://dx.doi.org/10.1046/j.1523-1755.2000.00152.x

[6]   Gerntholtz, T.E., Goetsch, S.J.W. and Katz, I. (2006) HIV-Related Nephropathy: A South African Perspective. Kidney International, 69, 1885-1891. http://dx.doi.org/10.1038/sj.ki.5000351

[7]   Wyatt, C.M. and Klotman, P.E. (2007) HIV-1 and HIV-Associated Nephropathy 25 Years Later. Clinical Journal of the American Society of Nephrology, 2, S20-S24.

[8]   Genovese, G., Friedman, D.J., Ross, M.D., Lecordier, L., Uzureau, P., Freedman, B.I., Bowden, D.W., Langefeld, C.D., Oleksyk, T.K., Uscinski Knob, A.L., Bernhardy, A.J., Hicks, P.J., Nelson, G.W., Vanhollebeke, B., Winkler, C.A., Kopp, J.B., Pays, E. and Pollak, M.R. (2010) Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science, 329, 841-845.
http://dx.doi.org/10.1126/science.1193032

[9]   Han, T.M., Naicker, S., Ramdial, P.K. and Assounga, A.G. (2006) A Cross-Sectional Study of HIV-Seropositive Patients with Varying Degrees of Proteinuria in South Africa. Kidney International, 69, 2243-2250. http://dx.doi.org/10.1038/sj.ki.5000339

[10]   Wyatt, C.M. (2008) HIV and the Kidney: A Spotlight on Racial Disparities. Journal of Infectious Diseases, 197, 1490-1492. http://dx.doi.org/10.1086/587995

[11]   Lucas, G.M., Lau, B., Atta, M.G., Fine, D.M., Keruly, J. and Moore, R.D. (2008) Chronic Kidney Disease Incidence, and Progression to End-Stage Renal Disease, in HIV-Infected Individuals: A Tale of Two Races. The Journal of Infectious Diseases, 197, 1548-1557. http://dx.doi.org/10.1086/587994

[12]   Wyatt, C.M. and Klotman, P.E. (2007) HIV-1 and HIV-Associated Nephropathy 25 Years Later. Clinical Journal of the American Society of Nephrology, 2, S20-S24. http://dx.doi.org/10.2215/CJN.03561006

[13]   Schwartz, E.J., Szczech, L.A., Ross, M.J., Klotman, M.E., Winston, J.A. and Klotman, P.E. (2005) Highly Active Antiretroviral Therapy and the Epidemic of HIV+ End-Stage Renal Disease. Journal of the American Society of Nephrology, 16, 2412-2420. http://dx.doi.org/10.1681/ASN.2005040340

[14]   Bigé, N., Lanternier, F., Viard, J.-P., Kamgang, P., Daugas, E., Elie, C., Jidar, K., Walker-Combrouze, F., Peraldi, M.-N., Isnard-Bagnis, C., Servais, A., Lortholary, O., Noël, L.-H. and Bollée, G. (2012) Presentation of HIV-Associated Nephropathy and Outcome in HAART-Treated Patients. Nephrology Dialysis Transplantation, 27, 1114-1121.http://dx.doi.org/10.1093/ndt/gfr376

[15]   Gallant, J.E., Staszewski, S., Pozniak, A.L., De Jesus, E., Suleiman, J.M.A.H., Miller, M.D., Coakley, D.F., Lu, B., Toole, J.J. and Cheng, A.K. (2004) Efficacy and Safety of Tenofovir DF vs. Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. JAMA, 292, 191-201.http://dx.doi.org/10.1001/jama.292.2.191

[16]   Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo, R.E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J.J. and Cheng, A.K. (2006) Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. New England Journal of Medicine, 354, 251-260. http://dx.doi.org/10.1056/NEJMoa051871

[17]   Izzedine, H., Hulot, J.S., Vittecoq, D., Gallant, J.E., Staszewski, S., Launay-Vacher, V., Cheng, A. and Deray, G. (2005) Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Antiretroviral-Naive HIV-1-Infected Patients. Data from a Double-Blind Randomized Active-Controlled Multicentre Study. Nephrology Dialysis Transplantation, 20, 743-746. http://dx.doi.org/10.1093/ndt/gfh658

[18]   Zimbabwe Advisory, National Drug and Therapeutics Policy (NDTPAC), Committee and the AIDS and TB Unit, Ministry of Health and Child Welfare (2010) Guidelines for Antiretroviral Therapy in Zimbabwe.

[19]   Yeh, K.C., Deutsch, P.J., Haddix, H., Hesney, M., Hoagland, V., Ju, W.D., Justice, S.J., Osborne, B., Sterrett, A.T., Stone, J.A., Woolf, E. and Waldman, S. (1998) Single-Dose Pharmacokinetics of Indinavir and the Effect of Food. Antimicrobial Agents and Chemotherapy, 42, 332-338.

[20]   Fernandez-Fernandez, B., Montoya-Ferrer, A., Sanz, A.B., Sanchez-Niño, M.D., Izquierdo, M.C., Poveda, J., Sainz-Prestel, V., Ortiz-Martin, N., Parra-Rodriguez, A., Selgas, R., Ruiz-Ortega, M., Egido, J. and Ortiz, A. (2011) Tenofovir Nephrotoxicity: 2011 Update. AIDS Research and Treatment, 2011, Article ID: 354908.http://dx.doi.org/10.1155/2011/354908

[21]   Kalyesubula, R. and Perazella, M.A. (2011) Nephrotoxicity of HAART. AIDS Research and Treatment, 2011, Article ID: 562790.

[22]   Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A.N., Ledergerber, B. and Lundgren, J.D. (2010) Estimated Glomerular Filtration Rate, Chronic Kidney Disease and Antiretroviral Drug Use in HIV-Positive Patients. AIDS, 24, 1667-1678.
http://dx.doi.org/10.1097/QAD.0b013e328339fe53

[23]   Mocroft, A., Kirk, O., Gatell, J., Reiss, P., Gargalianos, P., Zilmer, K., Beniowski, M., Viard, J.-P., Staszewski, S. and Lundgren, J.D. (2007) Chronic Renal Failure among HIV-1-Infected Patients. AIDS, 21, 1119-1127.http://dx.doi.org/10.1097/QAD.0b013e3280f774ee

[24]   Sax, P.E., Gallant, J.E. and Klotman, P.E. (2007) Renal safety of Tenofovir Disoproxil Fumarate. The AIDS Reader, 17, 90-92, 99-104, C3.

[25]   Cooper, R.D., Wiebe, N., Smith, N., Keiser, P., Naicker, S. and Tonelli, M. (2010) Systematic Review and Meta-Analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients. Clinical Infectious Diseases, 51, 496-505. http://dx.doi.org/10.1086/655681

[26]   Hall, A.M., Hendry, B.M., Nitsch, D. and Connolly, J.O. (2011) Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients. American Journal of Kidney Diseases, 57, 773-780.

[27]   Longenecker, J.C., Coresh, J., Klag, M.J., Levye, A.S., Martin, A.A., Fink, N.E. and Powe, N.R. (2000) Validation of Comorbid Conditions on the End-Stage Renal Disease Medical Evidence Report: The CHOICE Study. Journal of the American Society of Nephrology, 11, 520-529.

[28]   Foster, M.C., Rawlings, A.M., Marrett, E., Neff, D., Willis, K., Inker, L.A., Coresh, J. and Selvin, E. (2013) Cardiovascular Risk Factor Burden, Treatment, and Control among Adults with Chronic Kidney Disease in the United States. American Heart Journal, 166, 150-156.
http://dx.doi.org/10.1016/j.ahj.2013.03.016

[29]   Parikh, N.I., Hwang, S.-J., Larson, M.G., Meigs, J.B., Levy, D. and Fox, C.S. (2006) Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Overall Burden and Rates of Treatment and Control. Archives of Internal Medicine, 166, 1884-1891. http://dx.doi.org/10.1001/archinte.166.17.1884

[30]   Roberts, M.A., Hare, D.L., Ratnaike, S. and Ierino, F.L. (2006) Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. American Journal of Kidney Diseases, 48, 341-360.http://dx.doi.org/10.1053/j.ajkd.2006.06.005

[31]   Ando, M., Yanagisawa, N., Ajisawa, A., Tsuchiya, K. and Nitta, K. (2011) Kidney Tubular Damage in the Absence of Glomerular Defects in HIV-Infected Patients on Highly Active Antiretroviral Therapy. Nephrology Dialysis Transplantation, 26, 3224-3229. http://dx.doi.org/10.1093/ndt/gfr020

[32]   Ando, M., Tsuchiya, K. and Nitta, K. (2012) How to Manage HIV-Infected Patients with Chronic Kidney Disease in the HAART Era. Clinical and Experimental Nephrology, 16, 363-372.
http://dx.doi.org/10.1007/s10157-012-0585-7

[33]   Goulet, J.L., Fultz, S.L., Rimland, D., Butt, A., Gibert, C., Rodriguez-Barradas, M., Bryant, K. and Justice, A.C. (2007) Aging and Infectious Diseases: Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? Clinical Infectious Diseases, 45, 1593-1601.
http://dx.doi.org/10.1086/523577

[34]   Wikman, P., Safont, P., Del Palacio, M., Moreno, A., Moreno, S. and Casado, J.L. (2013) The Significance of Antiretroviral-Associated Acute Kidney Injury in a Cohort of Ambulatory Human Immunodeficiency Virus-Infected Patients. Nephrology Dialysis Transplantation, 28, 2073-2081.
http://dx.doi.org/10.1093/ndt/gft210

[35]   Griffin, L. and Standridge, J.B. (2012) A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications. Current Hypertension Reviews, 8, 196-226.http://dx.doi.org/10.2174/157340212803530394

[36]   Gupta, S.K., Eustace, J.A., Winston, J.A., Boydstun, I.I., Ahuja, T.S., Rodriguez, R.A., Tashima, K.T., Roland, M., Franceschini, N., Palella, F.J., Lennox, J.L., Klotman, P.E., Nachman, S.A., Hall, S.D. and Szczech, L.A. (2005) Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 40, 1559-1585.http://dx.doi.org/10.1086/430257

[37]   Gardner, L.I., Holmberg, S.D., Williamson, J.M., Szczech, L.A., Carpenter, C.C.J., Rompalo, A.M., Schuman, P., Klein, R.S. and Al, G.E.T. (2003) Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes, 32, 203-209.

[38]   Amin, S., Clarke, S.E. and Halai, M. (2014) British National Formulary. March-Se. BMJ Group and the Royal Pharmaceutical Society of Great Britain.

[39]   Aberg, J.A., Gallant, J.E., Ghanem, K.G., Emmanuel, P., Zingman, B.S. and Horberg, M.A., Infectious Diseases Society of America (2014) Primary Care Guidelines for the Management of Persons Infected with HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 58, e1-e34.http://dx.doi.org/10.1093/cid/cit665

[40]   Kalyesubula, R. and Perazella, M.A. (2011) Nephrotoxicity of HAART. AIDS Research and Treatment, 2011, Article ID: 562790. http://dx.doi.org/10.1155/2011/562790

[41]   Winston, J.A., Klotman, M.E. and Klotman, P.E. (1999) HIV-Associated Nephropathy Is a Late, Not Early, Manifestation of HIV-1 Infection. Kidney International, 55, 1036-1040.
http://dx.doi.org/10.1046/j.1523-1755.1999.0550031036.x

[42]   Chandisarewa, W., Stranix-Chibanda, L., Chirapa, E., Miller, A., Simoyi, M., Mahomva, A., Maldonado, Y. and Shetty, A.K. (2007) Routine Offer of Antenatal HIV Testing (‘Opt-Out’ Approach) to Prevent Mother-to-Child Transmission of HIV in Urban Zimbabwe. Bulletin of the World Health Organization, 85, 843-850.http://dx.doi.org/10.2471/BLT.06.035188

[43]   Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International (2012) Zimbabwe Demographic and Health Survey 2010-11.

[44]   Ministry of Health & Child Welfare—Zimbabwe (2004) Prevention of Opportunistic Infections—Training Course for Health Care Providers, February 2004.

 
 
Top